7 news items
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
ARDX
21 May 24
if there was a difference in efficacy between patients who had prior use of other IBS-C prescription medications and those without. A clinically meaningful response
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
ARDX
16 May 24
in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers
Ardelyx To Present Additional Data Supporting First-In-Class IBSRELA For Adults With Irritable Bowel Syndrome With Constipation At The 2024 Digestive Disease Week Conference
ARDX
7 May 24
), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
ARDX
7 May 24
), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
ARDX
2 May 24
approval by the U.S. Food and Drug Administration of XPHOZAH in October 2023, Ardelyx continued to see a strong response from the nephrology community. U.S
s3xt4maz97ljqf6gmuco0gydix5r79rg932u7o1zo6gr9r38yema68kxzh7
ARDX
1 May 24
in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different
bbwq18mw99cm1 kp2aw1nhgel3mkv1rlyl7jyejhzu6
ARDX
5 Apr 24
', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ardelyx. This information provides a snapshot of how
- Prev
- 1
- Next